Pharmacogénétique et thérapies ciblées 113
6. Amador ML, Oppenheimer D, Perea S, et al. (2004) An epidermal growth factor receptor
intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors.
Cancer Res; 64: 139-143.
7. Nagatsuka H, Ishiwari Y, Tsujigiwa H, et al. (2001) Quantitation of epidermal growth factor
receptor gene amplification by competitive polymerase chain reaction in pre-malignant
and malignant oral epithelial lesions. Oral Oncol; 37: 599-604.
8. Dahan L, Norguet E, Etienne-Grimaldi MC, et al. (2011) Pharmacogenetic profiling
and cetuximab outcome in patients with advanced colorectal cancer. BMC Cancer. Nov
25;11:496.
9. Papewalis J, Nikitin AY, Rajewsky MF. (1991) G to A polymorphism at amino acid codon
655 of the human erbB-2/HER-2 gene. Nucl Acid Res; 19: 5452.
10. Segatto O, King CR, Pierce JH, et al. (1988) Different structural alterations up-regulate
in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene. Mol Cell
Biol; 8: 5570-5574.
11. Xie D, Shu WO, Deng Z, et al. (2000) Population based case-control study of HER2
genetic polymorphism and breast cancer risk. J Natl Cancer Inst; 92: 412-416.
12. Beauclair S, Formento P, Fischel JL, et al. (2007) Role of the HER2 [Ile655Val] genetic
polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity. Ann
Oncol. 2007 Aug;18(8): 1335-41.
13. Roca L, Diéras V, Roché H, et al. (2013) Correlation of HER2, FCGR2A, and FCGR3A
gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of
patients from UNICANCER-PACS 04 trial. Breast Cancer Res Treat. Jun;139(3):789-800.
14. Formento JL, Etienne-Grimaldi MC, Francoual M, et al. (2009) Influence of the VEGF-A
936C>T germinal polymorphism on tumoral VEGF expression in head and neck cancer.
Pharmacogenomics. Aug;10(8): 1277-83.
15. Koukourakis MI, Papazoglou D, Giatromanolaki A, et al. (2004) VEGF gene sequence
variation defines VEGF gene expression status and angiogenic activity in non-small cell
lung cancer. Lung Cancer. Dec;46(3): 293-8.
16. Krippl P, Langsenlehner U, Renner W, et al. (2003) A common 936 C/T gene polymorphism
of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J
Cancer. Sep 10;106(4): 468-71.
17. Ku KT, Wan L, Peng HC, et al. (2005) Vascular endothelial growth factor gene-460 C/T
polymorphism is a biomarker for oral cancer. Oral Oncol. May;41(5): 497-502.
18. Lee SJ, Lee SY, Jeon HS, et al. (2005) Vascular endothelial growth factor gene polymorphisms
and risk of primary lung cancer. Cancer Epidemiol Biomarkers Prev. Mar;14(3): 571-5.
19. Jain L, Vargo CA, Danesi R, et al. (2009) The role of vascular endothelial growth factor
SNPs as predictive and prognostic markers for major solid tumors. Mol Cancer Ther.
Sep;8(9): 2496-508.
20. Etienne-Grimaldi MC, Formento P, Degeorges A, et al. (2011) Prospective analysis of the
impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based
therapy in metastatic breast cancer patients. Br J Clin Pharmacol. 2011 Jun;71(6):921-8.
21. Barrière J, Formento JL, Milano G et al. (2010) CYP2D6 polymorphisms and tamoxifen:
therapeutic perspectives in the management of hormonodependent breast cancer patients.
Bull Cancer. Mar;97(3): 311-20.
22. Goetz MP, Knox SK, Suman VJ, et al. (2007) The impact of cytochrome P450
2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat.
Jan;101(1):113-21.
23. Schroth W, Goetz MP, Hamann U, et al. (2009) Association between CYP2D6
polymorphisms and outcomes among women with early stage breast cancer treated with
tamoxifen. JAMA. Oct 7;302(13): 1429-36.
24. Schroth W, Hamann U, Fasching PA, et al. (2010) CYP2D6 polymorphisms as predictors
of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism
coverage improves risk stratification. Clin Cancer Res. Sep 1;16(17): 4468-77.
6. Amador ML, Oppenheimer D, Perea S, et al. (2004) An epidermal growth factor receptor
intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors.
Cancer Res; 64: 139-143.
7. Nagatsuka H, Ishiwari Y, Tsujigiwa H, et al. (2001) Quantitation of epidermal growth factor
receptor gene amplification by competitive polymerase chain reaction in pre-malignant
and malignant oral epithelial lesions. Oral Oncol; 37: 599-604.
8. Dahan L, Norguet E, Etienne-Grimaldi MC, et al. (2011) Pharmacogenetic profiling
and cetuximab outcome in patients with advanced colorectal cancer. BMC Cancer. Nov
25;11:496.
9. Papewalis J, Nikitin AY, Rajewsky MF. (1991) G to A polymorphism at amino acid codon
655 of the human erbB-2/HER-2 gene. Nucl Acid Res; 19: 5452.
10. Segatto O, King CR, Pierce JH, et al. (1988) Different structural alterations up-regulate
in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene. Mol Cell
Biol; 8: 5570-5574.
11. Xie D, Shu WO, Deng Z, et al. (2000) Population based case-control study of HER2
genetic polymorphism and breast cancer risk. J Natl Cancer Inst; 92: 412-416.
12. Beauclair S, Formento P, Fischel JL, et al. (2007) Role of the HER2 [Ile655Val] genetic
polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity. Ann
Oncol. 2007 Aug;18(8): 1335-41.
13. Roca L, Diéras V, Roché H, et al. (2013) Correlation of HER2, FCGR2A, and FCGR3A
gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of
patients from UNICANCER-PACS 04 trial. Breast Cancer Res Treat. Jun;139(3):789-800.
14. Formento JL, Etienne-Grimaldi MC, Francoual M, et al. (2009) Influence of the VEGF-A
936C>T germinal polymorphism on tumoral VEGF expression in head and neck cancer.
Pharmacogenomics. Aug;10(8): 1277-83.
15. Koukourakis MI, Papazoglou D, Giatromanolaki A, et al. (2004) VEGF gene sequence
variation defines VEGF gene expression status and angiogenic activity in non-small cell
lung cancer. Lung Cancer. Dec;46(3): 293-8.
16. Krippl P, Langsenlehner U, Renner W, et al. (2003) A common 936 C/T gene polymorphism
of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J
Cancer. Sep 10;106(4): 468-71.
17. Ku KT, Wan L, Peng HC, et al. (2005) Vascular endothelial growth factor gene-460 C/T
polymorphism is a biomarker for oral cancer. Oral Oncol. May;41(5): 497-502.
18. Lee SJ, Lee SY, Jeon HS, et al. (2005) Vascular endothelial growth factor gene polymorphisms
and risk of primary lung cancer. Cancer Epidemiol Biomarkers Prev. Mar;14(3): 571-5.
19. Jain L, Vargo CA, Danesi R, et al. (2009) The role of vascular endothelial growth factor
SNPs as predictive and prognostic markers for major solid tumors. Mol Cancer Ther.
Sep;8(9): 2496-508.
20. Etienne-Grimaldi MC, Formento P, Degeorges A, et al. (2011) Prospective analysis of the
impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based
therapy in metastatic breast cancer patients. Br J Clin Pharmacol. 2011 Jun;71(6):921-8.
21. Barrière J, Formento JL, Milano G et al. (2010) CYP2D6 polymorphisms and tamoxifen:
therapeutic perspectives in the management of hormonodependent breast cancer patients.
Bull Cancer. Mar;97(3): 311-20.
22. Goetz MP, Knox SK, Suman VJ, et al. (2007) The impact of cytochrome P450
2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat.
Jan;101(1):113-21.
23. Schroth W, Goetz MP, Hamann U, et al. (2009) Association between CYP2D6
polymorphisms and outcomes among women with early stage breast cancer treated with
tamoxifen. JAMA. Oct 7;302(13): 1429-36.
24. Schroth W, Hamann U, Fasching PA, et al. (2010) CYP2D6 polymorphisms as predictors
of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism
coverage improves risk stratification. Clin Cancer Res. Sep 1;16(17): 4468-77.